衰弱对高龄(≥80岁)ICU患者ICU死亡率、30天死亡率及治疗强度的影响
这项由欧洲重症医学会组织的跨国前瞻性队列研究于2016年10月至2017年5月纳入21个欧洲国家311个ICU中连续收治的≥80岁患者,共5021例(中位年龄84岁,IQR 81-86岁;女性2404例,47.9%),入住ICU时用临床衰弱量表评估衰弱,主要终点为ICU死亡率和30天死亡率。总体ICU死亡率为22.1%,30天死亡率为32.6%;43.1%的患者CFS≥5分(衰弱),衰弱与30天生存独立相关(HR 1.54;95%CI 1.38-1.73,衰弱 vs 非衰弱)。23.8%的患者在ICU期间未接受通气、血管活性药物或肾脏替代治疗等特定ICU治疗。作者认为这些发现支持将衰弱评估加入该患者群体的临床评估。
要点
- 在≥80岁ICU患者中,入住ICU时CFS≥5分的衰弱与30天生存独立相关(HR 1.54;95%CI 1.38-1.73,衰弱 vs 非衰弱)。
- 该跨国前瞻性队列共纳入5021例≥80岁患者,总体ICU死亡率为22.1%,30天死亡率为32.6%。
- 43.1%的≥80岁ICU患者CFS≥5分(衰弱),CFS各等级与短期生存呈反向关联。
- 23.8%的患者在ICU期间未接受通气、血管活性药物或肾脏替代治疗等特定ICU治疗。
- CFS在入住ICU时评估,缺失数据非常少,作者支持将衰弱加入该患者群体的临床评估。
适用人群与场景
- 欧洲21个国家311个ICU在3个月纳入期内连续收治的前20例≥80岁ICU患者,最终分析5021例,中位年龄84岁(IQR 81-86岁),女性2404例(47.9%)。
- 入院类型为急性者4215例(83.9%)。
诊断标准与关键阈值
- 衰弱评估:入住ICU时使用临床衰弱量表(Clinical Frailty Scale),CFS≥5分定义为衰弱,本队列中占43.1%。
研究设计与关键结果
- 研究设计:欧洲重症医学会组织的跨国前瞻性队列研究,2016年10月至2017年5月,30天随访,21个欧洲国家311个ICU参与。
- 主要终点:总体ICU死亡率为22.1%,30天死亡率为32.6%。
- 衰弱与结局:CFS≥5分(衰弱)与非衰弱相比,30天生存的HR为1.54(95%CI 1.38-1.73),为独立相关。
- 治疗强度:23.8%的患者在ICU期间未接受通气、血管活性药物或肾脏替代治疗。
- CFS各等级与短期生存呈反向关联,量表缺失数据非常少。
证据类型、等级与局限
- 证据类型:跨国前瞻性队列研究(ClinicalTrials.gov ID:NCT03134807)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些发现支持将衰弱评估(临床衰弱量表)加入≥80岁ICU患者的临床评估。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Very old critical ill patients are a rapid expanding group in the ICU. Indications for admission, triage criteria and level of care are frequently discussed for such patients. However, most relevant outcome studies in this group frequently find an increased mortality and a reduced quality of life in survivors. The main objective was to study the impact of frailty compared with other variables with regards to short-term outcome in the very old ICU population.
METHODS: A transnational prospective cohort study from October 2016 to May 2017 with 30 days follow-up was set up by the European Society of Intensive Care Medicine. In total 311 ICUs from 21 European countries participated. The ICUs included the first consecutive 20 very old (≥ 80 years) patients admitted to the ICU within a 3-month inclusion period. Frailty, SOFA score and therapeutic procedures were registered, in addition to limitations of care. For measurement of frailty the Clinical Frailty Scale was used at ICU admission. The main outcomes were ICU and 30-day mortality and survival at 30 days.
RESULTS: A total of 5021 patients with a median age of 84 years (IQR 81-86 years) were included in the final analysis, 2404 (47.9%) were women. Admission was classified as acute in 4215 (83.9%) of the patients. Overall ICU and 30-day mortality rates were 22.1% and 32.6%. During ICU stay 23.8% of the patients did not receive specific ICU procedures: ventilation, vasoactive drugs or renal replacement therapy. Frailty (values ≥ 5) was found in 43.1% and was independently related to 30-day survival (HR 1.54; 95% CI 1.38-1.73) for frail versus non-frail.
CONCLUSIONS: Among very old patients (≥ 80 years) admitted to the ICU, the consecutive classes in Clinical Frailty Scale were inversely associated with short-term survival. The scale had a very low number of missing data. These findings provide support to add frailty to the clinical assessment in this patient group.
TRIAL REGISTRATION: ClinicalTrials.gov (ID: NCT03134807).
参考来源
- Flaatten H, De Lange DW, Morandi A, et al. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years). Intensive Care Med. 2017. PMID: 28936626. doi:10.1007/s00134-017-4940-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。